folder

A synthetic epoxyeicosatrienoic acid analog prevents the initiation of ischemic acute kidney injury

Authors

  • U. Hoff
  • G. Bubalo
  • M. Fechner
  • M. Blum
  • Y. Zhu
  • A. Pohlmann
  • J. Hentschel
  • K. Arakelyan
  • E. Seeliger
  • B. Flemming
  • D. Gürgen
  • M. Rothe
  • T. Niendorf
  • V.L. Manthati
  • J.R. Falck
  • M. Haase
  • W.H. Schunck
  • D. Dragun

Journal

  • Acta Physiologica

Citation

  • Acta Physiol e13297

Abstract

  • AIM: Imbalances in cytochrome P450 (CYP)-dependent eicosanoid formation may play a central role in ischemic acute kidney injury (AKI). We reported previously that inhibition of 20-hydroxyeicosatetraenoic acid (20-HETE) action ameliorated ischemia/reperfusion (I/R)-induced AKI in rats. Now we tested the hypothesis that enhancement of epoxyeicosatrienoic acid (EET) actions may counteract the detrimental effects of 20-HETE and prevent the initiation of AKI. METHODS: Male Lewis rats underwent right nephrectomy and ischemia was induced by 45 min clamping of the left renal pedicle followed by up to 48 h of reperfusion. Circulating CYP-eicosanoid profiles where compared in patients who underwent cardiac surgery with (n=21) and without (n=38) developing postoperative AKI. RESULTS: Ischemia induced an about 8-fold increase of renal 20-HETE levels, whereas free EETs were not accumulated. To compensate for this imbalance, a synthetic 14,15-EET analog was administered by intrarenal infusion before ischemia. The EET analog improved renal reoxygenation as monitored by in vivo parametric MRI during the initial 2 h reperfusion phase. The EET analog improved PI3K- as well as mTORC2-dependent rephosphorylation of Akt, induced inactivation of GSK-3β, reduced the development of tubular apoptosis and attenuated inflammatory cell infiltration. The EET analog also significantly alleviated the I/R-induced drop in creatinine clearance. Patients developing postoperative AKI featured increased preoperative 20-HETE and 8,9-EET levels. CONCLUSIONS: Pharmacological interventions targeting the CYP-eicosanoid pathway could offer promising new options for AKI prevention. Individual differences in CYP-eicosanoid formation may contribute to the risk of developing AKI in clinical settings.


DOI

doi:10.1111/apha.13297